Clinical spectrum and outcome determinants in persistent pulmonary hypertension of the newborn in a tertiary care centre: a cross-sectional study

Deepti Omkar Pai; Paramanand Andankar; Lavanya Peruri; Shakuntala Prabhu; Srinivas Lakshmivenkateshiah

doi:10.18203/2349-3291.ijcp20263813

Authors

Deepti Omkar Pai Department of Pediatrics, Jupiter Hospital, Thane, Maharashtra, India
Paramanand Andankar Department of Pediatrics, Jupiter Hospital, Thane, Maharashtra, India
Lavanya Peruri Department of Pediatrics, Jupiter Hospital, Thane, Maharashtra, India
Shakuntala Prabhu Department of Pediatrics, Bai Jerbai Wadia Hospital for Children, Mumbai, Maharashtra, India
Srinivas Lakshmivenkateshiah Department of Cardiology, KIMS Hospital, Thane, Maharashtra, India

DOI:

https://doi.org/10.18203/2349-3291.ijcp20263813

Keywords:

Persistent pulmonary hypertension in neonates, Echocardiography, Right ventricular systolic pressure, High frequency oscillatory ventilation, Inhaled nitric oxide

Abstract

Background: Persistent pulmonary hypertension of the newborn (PPHN) is a serious neonatal condition characterized by elevated pulmonary vascular resistance after birth, resulting in hypoxemia. It may be associated with perinatal risk factors such as birth asphyxia, meconium aspiration syndrome, respiratory distress syndrome, and sepsis. Early diagnosis and appropriate management are essential to improve neonatal outcomes. This study aims to assess the risk factors, clinical profile, treatment modalities, and outcomes in newborns with PPHN.

Methods: This cross-sectional study was conducted in the Level 3 neonatal unit in Western India, data of the neonates diagnosed to have PPHN on echocardiography admitted during the period from October 2019 till July 2021 were recorded. The normality of the continuous data was tested by Shapiro-Wilk test. The continuous variables were analysed by Mann-Whitney U test and Kruskal-Wallis test. Post-hoc Dunn’s test is used to do pairwise comparisons. Categorical data is analysed using Fisher’s Exact test. P<0.05 are accepted as indicative of statistical significance.

Results: Total 36 neonates were included in the study with incidence of 8.2 per 1000 live births with mortality of 27.8% with better survival in inborn neonates. Resuscitation at birth in neonates correlated with the severity of PPHN. ABG parameters showing metabolic and respiratory acidosis, hypoxemia and poor oxygenation indices were associated with mortality. On Echocardiography, parameters like right to left shunt across PDA/PFO, right ventricular dysfunction and septal position deviated to left were associated with mortality. Requirement of surfactant, multiple inotropes, HFOV and iNO were independently associated with mortality.

Conclusions: PPHN is a disease with significant mortality and long-term morbidity which can be prevented with timely intervention, targeted Echocardiography, monitoring of parameters and requires multiple modalities of treatment.

References

Sardar S, Pal S, Mishra R. A retrospective study on the profile of persistent pulmonary hypertension of newborn in a tertiary care unit of Eastern India. J Clin Neonatol. 2020;9(1):18-26.

Lakshminrusimha S, Keszler M. Persistent pulmonary hypertension of the newborn. Neo Reviews. 2015;16(12):e680-92.

Huang Y, Yang T, Liang X, Chen Y, Zhou P, Yu Z, et al. Global, regional and national trends in the burden of persistent pulmonary hypertension of the newborn and essentials of its management from 1993 to 2023: a scoping review. Front Pediatr. 2025;13:1502385.

Arshad MS, Adnan M, Anwar-Ul-Haq HM, Zulqarnain A. Postnatal causes and severity of persistent pulmonary hypertension of newborn. Pak J Med Sci. 2021;37(5):1387-91.

Mohsen AH, Amin AS. Risk factors and outcomes of persistent pulmonary hypertension of the newborn in the neonatal intensive care unit of Al-Minya University Hospital in Egypt. J Clin Neonatol. 2013;2 (2):78-82.

Nakwan N, Jain S, Kumar K, Hosono S, Hammoud M, Elsayed YY, et al. An Asian multicenter retrospective study on persistent pulmonary hypertension of the newborn: incidence, etiology, diagnosis, treatment and outcome. J Matern Fetal Neonatal Med. 2020;33(12):2032-7.

Bendapudi P, Rao GG, Greenough A. Diagnosis and management of persistent pulmonary hypertension of the newborn. Paediatr Respir Rev. 2015;16(3):157-61.

Nair J, Lakshminrusimha S. Update on PPHN: mechanisms and treatment. Semin Perinatol. 2014;38(2):78-91.

Martinho S, Adão R, Leite-Moreira AF, Brás-Silva C. Persistent pulmonary hypertension of the newborn: pathophysiological mechanisms and novel therapeutic approaches. Front Pediatr. 2020;8:342.

Pedersen J, Hedegaard ER, Simonsen U, Krüger M, Infanger M, Grimm D. Current and future treatments for persistent pulmonary hypertension in the newborn. Basic Clin Pharmacol Toxicol. 2018;123(4):392-406.

Malowitz JR, Forsha DE, Smith PB, Cotten CM, Barker PC, Tatum GH. Right ventricular echocardiographic indices predict poor outcomes in infants with persistent pulmonary hypertension of the newborn. Eur Heart J Cardiovasc Imaging. 2015;16(11):1224-31.

Mat Bah MN, Tan RYH, Razak H, Sapian MH, Abdullah N, Alias EY. Survival and associated risk factors for mortality among infants with persistent pulmonary hypertension of the newborn in Malaysia. J Perinatol. 2021;41(4):786-93.

Pakhathirathien P, Maneenil G, Thatrimontrichai A, Dissaneevate S, Praditaukrit M. Mortality prediction in newborns with persistent pulmonary hypertension: a comparison of four illness severity scores. Pediatr Pulmonol. 2025;60:e27484.

Kelly LE, Ohlsson A, Shah PS. Sildenafil for pulmonary hypertension in neonates. Cochrane Database Syst Rev. 2017;(8):CD005494.

Vargas-Origel A, Gómez-Rodríguez G, Aldana-Valenzuela C, Vela-Huerta MM, Alarcón-Santos SB, Amador-Licona N. The use of sildenafil in persistent pulmonary hypertension of the newborn. Am J Perinatol. 2010;27(3):225-30.